Success Stories: Successful I-140 NIW Approval Achieved for Researcher in the Field of Pharmaceutical Science with Our Dedicated Support
Client’s Testimonial:
“Thank you very much for your support throughout this process! It was truly a pleasure working with your team.”
On March 24th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Researcher in the Field of Pharmaceutical Science (Approval Notice).
General Field: Pharmaceutical Science
Position at the Time of Case Filing: Researcher
Country of Origin: South Korea
State of Residence at the Time of Filing: South Korea
Approval Notice Date: March 24th, 2025
Processing Time: 1 month, 24 days (Premium Processing Requested)
Case Summary:
“By leveraging [Client’s] informative insights into oriental foliage, the United States is able to retain its standing as a leader in pharmaceutical research while also reducing the global burden of cancer.”
The excerpt above is drawn from one of two recommendation letters submitted in support of our client’s I-140 National Interest Waiver (NIW) petition. She is a researcher from South Korea with a Master’s degree in pharmacy. Leveraging our extensive experience, we employed a strategic, individualized approach to develop a persuasive, documented petition tailored to her strengths.
As an expert in the field of pharmaceutical science, our client’s proposed endeavor is to continue her research on integrating advanced technologies from interdisciplinary domains and utilizing computational approaches to develop novel drug candidates and improve drug delivery systems to create more effective, affordable, and stable pharmaceutical or biopharmaceutical medications for chronic diseases such as cancer, diabetes, hypertension, and neurodegenerative diseases.
Her proposed endeavor holds significant merit and serves the national interest by addressing urgent public health challenges while enhancing the overall management of chronic diseases in the United States. The potential impact of her work includes improving patient outcomes, elevating the quality of life, and reinforcing the resilience of the U.S. healthcare system.
To further support her case, we emphasized her strong academic and professional credentials:
- She has authored 12 peer-reviewed journal articles (5 of them first- or co-first-authored), 10 conference abstracts (3 of them first-authored), 1 patent, and 2 patent application publications in no fewer than 8 highly ranked peer-reviewed journals.
- Her works have been cited a total of 281 times, according to Google Scholar.
- Her study has received funding from the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry, and Fisheries and the National Research Foundation of Korea. This support of her research therefore further validates the importance and credibility of her work.
Given her advanced degree, proven record of success, and the clear alignment of her research with the NIW eligibility criteria, her petition was approved in just 1 month and 24 days through premium processing. We are proud to have played a role in her journey and look forward to her continued contributions to the field of pharmaceutical science.